Insmed Discontinues Brensocatib Development, Shares Plunge 16.1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Businesswire
- Legal Investigation Initiated: The Schall Law Firm is investigating Insmed for potential violations of securities laws, focusing on whether the company issued false or misleading statements, which highlights potential compliance risks in its information disclosure practices.
- Clinical Trial Failure: On December 17, 2025, Insmed announced that the Phase 2b BiRCh study of brensocatib failed to meet its primary and secondary efficacy endpoints in chronic rhinosinusitis patients, indicating a significant setback in its R&D pipeline that may affect investor confidence moving forward.
- Stock Price Plummets: Following this announcement, Insmed's shares fell by nearly 16.1% the next day, which not only impacts existing shareholders' returns but also raises concerns among potential investors regarding the company's future prospects.
- R&D Strategy Shift: Insmed's decision to discontinue brensocatib development signifies a major shift in its R&D strategy, necessitating a reassessment of its product pipeline and market positioning to address the crisis of investor trust.
INSM
$176.34+Infinity%1D
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 200.31 USD with a low forecast of 145.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 177.880
Low
145.00
Averages
200.31
High
240.00
Current: 177.880
Low
145.00
Averages
200.31
High
240.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
